✦ LIBER ✦

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

✍ Scribed by Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary Allen; Kent J. Weinhold; Guido Ferrari; Scott D. Parker; M. Juliana McElrath; Sharon E. Frey; Jonathan D. Fuchs; Michael C. Keefer; Michael D. Lubeck; Michael Egan; Ralph Braun; John H. Eldridge; Barton F. Haynes; Lawrence Corey

Book ID: 116961054
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 611 KB
Volume: 27
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2008.10.051

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I safety and immunogenicity tria

A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

✍ John S Lambert; Michael Keefer; Mark J Mulligan; David Schwartz; Jiri Mestecky; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 151 KB

An open-label, prospective phase I/II st

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer

✍ Meyer, Ralf G.; Korn, Stephanie; Micke, Patrick; Becker, Kai; Huber, Christoph; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Safety and immunogenicity of inactivated

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults

✍ Verdijk, Pauline; Rots, Nynke Y.; van Oijen, Monique G.C.T.; Oberste, M. Steven; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 415 KB

A phase I trial evaluating the safety an

A phase I trial evaluating the safety and immunogenicity of a HER-2 protein vaccine in patients with breast cancer

✍ B Overmoyer; A Brufsky; B Volck; D Leach; A Oestergaard 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Safety and immunogenicity of a randomize

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene

✍ RJ O’Connell, VR Polonis, S Ratto-Kim, J Cox, LL Jagodzinski, J Malia… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 68 KB

A phase II trial of vaccination with aut

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

✍ Lorenzo Pilla; Roberto Patuzzo; Licia Rivoltini; Michele Maio; Elisabetta Pennac 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 454 KB